ChromaDex Corporation (Nasdaq: CDXC) — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. The filing identifies the registrant as ChromaDex Corporation; the request metadata names Niagen Bioscience, Inc.
Business context
ChromaDex is a bioscience company focused on healthy aging. Its principal business is the NR ingredient Niagen and consumer supplement Tru Niagen, alongside ingredient sales and analytical reference standards and services.
Financial performance
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $19.5 | $17.1 | $62.4 | $51.1 |
| Gross profit | $12.0 | $10.2 | $37.8 | $30.8 |
| Gross margin | 61.4% | 59.8% | 60.7% | 60.3% |
| Operating expenses | $13.1 | $13.3 | $43.3 | $48.0 |
| Operating loss | $(1.1) | $(3.1) | $(5.4) | $(17.2) |
| Net loss | $(1.0) | $(1.0) | $(5.1) | $(15.1) |
| Loss per share | $(0.01) | $(0.01) | $(0.07) | $(0.22) |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $6.5 | $(14.8) |
Q3 sales rose 14%; nine-month sales rose 22%. Tru Niagen consumer-product sales were $17.4 million for the quarter and $51.9 million year to date. Nine-month segment sales were $51.9 million for Consumer Products (up 18%), $8.3 million for Ingredients (up 75%), and $2.2 million for Analytical Reference Standards and Services (down 6%).
Financial position and liquidity
At September 30, cash and cash equivalents were $26.8 million, including $26.6 million unrestricted and $0.2 million restricted. Working capital was approximately $27.7 million ($47.2 million current assets less $19.4 million current liabilities). The company reported no outstanding borrowings under its bank line of credit. Total liabilities were $26.2 million, including operating lease obligations of $3.8 million; finance lease obligations were immaterial. Inventory was $12.6 million, down from $14.7 million at year-end 2022.
Nine-month operating cash flow improved by $21.2 million year over year, reflecting a smaller net loss and better working-capital movements, including inventory management. Investing cash outflow was $0.1 million and financing cash outflow was nominal. The company reported an accumulated deficit of $190.6 million.
Material changes and unusual items
- Consumer Products growth reflected higher e-commerce and distributor sales. Ingredients revenue fell 22% in Q3, primarily due to timing of Niagen ingredient orders, but increased 75% year to date.
- Operating expenses declined 10% year to date, mainly due to lower legal costs, reduced headcount, and lower marketing expense. Q3 R&D included about $0.4 million of increased initiative spending, partly offset by a $0.3 million refund on a discontinued project.
- The prior-year comparison includes a $2.1 million Employee Retention Tax Credit benefit recognized in Q3 2022; no corresponding benefit was recorded in 2023. The company had received $0.9 million of the credit during the first nine months of 2023 and reported another $0.9 million receivable at quarter-end, subject to increased IRS scrutiny and slower processing.
- A $0.9 million year-to-date provision for doubtful receivables was recorded, primarily related to the Chapter 11 bankruptcy of iMedia Brands, which operated the ShopHQ sales channel.
- On October 26, 2023, the appeals court affirmed enforcement of the Elysium settlement in the New York action. The Supreme Court denied the company’s certiorari petition concerning the Delaware patent case on October 16; the company said it did not expect that decision to materially affect its NR business.
Outlook, risks, and contingencies
Management expects e-commerce to remain the primary sales-growth driver through 2023. It expects unrestricted cash and cash generated from sales to cover obligations for at least twelve months after issuance of the statements, while noting that it may seek additional capital for longer-term plans. Management identified recurring operating losses, historical negative operating cash flow, and inflation as liquidity-related concerns.
After quarter-end, the company obtained approximately $355,000 of rent abatement over about eight months. It also committed to purchase approximately $17.1 million of inventory from W.R. Grace during 2024, in addition to $4.5 million of remaining commitments for Q4 2023. The Grace supply agreement expires December 31, 2024; the company relies on Grace as its sole NR supplier and warns that failure to renew on satisfactory terms could materially harm results and its market position. Total inventory purchase obligations were reported at $21.6 million.
Key risks include continuing losses and potential need for financing; dependence on Tru Niagen and major customers; receivables concentration (about 85% among three customers, with A.S. Watson representing 52% of net receivables); inflation and consumer-demand uncertainty; sole-source NR supply; patent and other litigation; and product, regulatory, and cybersecurity risks. The company said it does not consider current receivables concentration a significant risk but acknowledged that customer payment delays or defaults could hurt cash flow. It also disclosed prior FDA/FTC warning letters concerning COVID-related statements, while stating it did not expect the matter’s ultimate resolution to be material.
Important facts for investors to verify
- Whether e-commerce growth and ingredient demand persist, and whether sales growth translates into sustained profitability.
- Cash generation, working-capital trends, the remaining ERTC receivable, and any financing plans or use of the bank credit line.
- Customer concentration, collection of major receivables, and any further bad-debt provisions.
- Execution of the $21.6 million inventory commitments and renewal terms for the Grace supply agreement before its 2024 expiration.
- Developments in litigation, regulatory matters, and the China joint venture’s required Blue Hat registration.